Henry Li, MS in Biotechnology

IHMA

Disclosure(s): Pfizer, Inc.: Advisor/Consultant

Poster(s):

• (P-1506) In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents against Pseudomonas aeruginosa Collected from Patients with Presumed Hospital- and Community-acquired Respiratory Tract Infections as a Part of the ATLAS Global Surveillance Program 2018-2022
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1507) In Vitro Activity of Ceftazidime-avibactam against Enterobacterales Isolates Producing Multiple β-lactamases Collected Globally as a Part of the ATLAS Global Surveillance Program from 2018-2022
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1508) In Vitro Activity of Aztreonam-avibactam against Enterobacterales Isolates Producing Multiple β-lactamases Collected Globally as a Part of the ATLAS Global Surveillance Program from 2018-2022
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1511) In Vitro Activity of Gepotidacin Against Molecularly Characterized Neisseria gonorrhoeae Isolates Exhibiting Reduced Susceptibility to Antibacterial Agents, 2018-2021
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT